Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 1.10% | 162.16 | 0.7% | $1254.93m | |
| PFE | Pfizer Inc. | 2.47% | 38.53 | 0.9% | $1060.23m | |
| MRK | Merck & Co., Inc. | 1.03% | 77.45 | 0.7% | $958.24m | |
| ABBV | AbbVie, Inc. | 1.02% | 107.98 | 1.9% | $778.70m | |
| BMY | Bristol-Myers Squibb Co. | 1.54% | 65.43 | 1.0% | $758.06m | |
| LLY | Eli Lilly & Co. | 1.76% | 189.20 | 1.1% | $575.67m | |
| AZN | AstraZeneca Plc | -0.18% | 50.74 | 1.2% | $463.76m | |
| GSK | GlaxoSmithKline Plc | 0.21% | 37.77 | 0.2% | $217.86m | |
| NVS | Novartis AG | 0.95% | 88.03 | 0.2% | $157.01m | |
| RPRX | Royalty Pharma Plc | 0.53% | 41.87 | 0.2% | $143.72m | |
| VTRS | Viatris, Inc. | 0.90% | 13.40 | 0.0% | $127.48m | |
| CVAC | CureVac NV | 5.04% | 109.29 | 0.0% | $96.11m | |
| RGEN | Repligen Corp. | -0.13% | 213.30 | 6.8% | $86.07m | |
| NVO | Novo Nordisk A/S | 0.95% | 72.19 | 0.1% | $62.10m | |
| SNY | Sanofi | 1.20% | 51.30 | 0.2% | $61.19m |
Company Profile
Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company that develops IRX-2, a novel hd-IL-2 based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells. In a Phase 2a clinical trial, IRX-2 demonstrated an increase in tumor infiltrating lymphocytes, which was associated with a survival benefit in patients with head and neck cancer. The company is headquartered in New York, NY.